Literature DB >> 27636538

An enzyme immunoassay for determining epidermal growth factor (EGF) in human serum samples using an ultramicroanalytical system.

Elisa María Castells Martínez1, Ruben Del Valle2, Ernesto Carlos González1, Antonio Melchor3, Pedro Lucio Pérez1, Idania González4, Adriana Carr4, Kalet León4.   

Abstract

Human epidermal growth factor is a small peptide consisting of 53 amino acid residues, which stimulates cell proliferation and is associated with several human carcinomas. A simple sandwich-type ultramicroELISA assay (UMELISA), based on the advantages of high affinity reaction between streptavidin and biotin has been developed for the measurement of EGF in human serum samples. Strips coated with a high affinity monoclonal antibody directed against EGF are used as solid phase, to ensure the specificity of the assay. The EGF assay was completed in 18 hr, with a measuring range of 39-2500 pg/mL. The intra- and inter-assay coefficients of variation were 4.4-7.3% and 0-5.1%, respectively, depending on the EGF concentrations evaluated. Percentage recovery ranged from 96-104%. Regression analysis showed a good correlation with the commercially available Human EGF Immunoassay Quantikine® ELISA kit (n = 130, r = 0.92, P < 0.01). The analytical performance characteristics of our UMELISA EGF endorse its use for the quantification of EGF in human serum samples.

Entities:  

Keywords:  CIMAVax-EGF®; SUMA technology; epidermic growth factor; ultramicroELISA

Mesh:

Substances:

Year:  2016        PMID: 27636538     DOI: 10.1080/15321819.2016.1236729

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN: 1532-1819


  2 in total

Review 1.  CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.

Authors:  Danay Saavedra; Tania Crombet
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

2.  Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Gisela María Suárez; Mauricio Catalá; Yadira Peña; Susana Portela; Ana Laura Añé-Kourí; Amnely González; Patricia Lorenzo-Luaces; Manuel Díaz; María de Los A Molina; Karla Pereira; Jenysbel de la C Hernández; Raúl Ramos; Mary Carmen Reyes; Nuris Ledón; Zaima Mazorra; Tania Crombet; Agustin Lage; Danay Saavedra
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.